Notable Downgrades: Breitburn Energy (BBEP), Ohr Pharmaceutical (OHRP), OncoGenex (OGXI), Microsoft (MSFT)

Analysts at Wunderlich downgraded Breitburn Energy Partners L.P. (BBEP) from ‘Hold‘ to ‘Sell‘ in a research report issued to clients on Monday.

The target price for BBEP is lowered from $9 to $4.

On valuation measures, BreitBurn Energy Partners L.P. stock it’s trading at a forward P/E multiple of 86.08x, and at a multiple of 1.72x this year’s estimated earnings. The t-12-month revenue at BreitBurn Energy Partners L.P. is $863.44 million. BBEP ‘s ROE for the same period is 14.64%.

Shares of the $1.10 billion market cap company are down 66.97% year-over-year and 12.85% year-to-date.

BreitBurn Energy Partners L.P., currently with a median Wall Street price target of $7.75 and a high target of $16.00, dropped $0.70 to $5.20 in recent trading.

The chart below shows where the equity has traded over the past 52-weeks.

Ohr Pharmaceutical, Inc. (OHRP) was reiterated a ‘Neutral’ by Chardan Capital Markets analysts on Monday. The broker also cut its price target on the stock to $3 from $8, implying 62.80% expected downside.

OHRP shares recently gained 7c to $2.81. The stock is down more than 80% year-over-year and has lost roughly 67% year-to-date. In the past 52 weeks, shares of the Charlotte, North Carolina-based company have traded between a low of $2.72 and a high of $14.60.

Ohr Pharmaceutical, Inc. closed Friday at $2.74. The name has a total market cap of $71.22 million.

OncoGenex Pharmaceuticals, Inc. (OGXI) was reiterated as ‘Buy’ with a $7 from $14 price target on Monday by Needham.

In the past 52 weeks, shares of Bothell, Washington-baaed biopharmaceutical company have traded between a low of $1.92 and a high of $12.09 with the 50-day MA and 200-day MA located at $2.28 and $2.31 levels, respectively. Additionally, shares of OGXI trade at a P/E ratio of N/A and have a Relative Strength Index (RSI) and MACD indicator of 40.01 and -0.13, respectively.

OGXI currently prints a one year loss of 81.64% and a year-to-date loss of more than 6%.

Microsoft Corporation (MSFT) was reiterated as ‘Outperform’ and the price target was lowered to $47 from $50 at RBC Capital Markets.

On valuation measures, Microsoft shares are currently priced at 16.60x this year’s forecasted earnings compared to the industry’s 34.96x earnings multiple. Ticker has a PEG and forward P/E ratio of 2.12 and 14.17, respectively. Price/Sales for the same period is 3.60 while EPS is $2.48. Currently there are 14 analysts that rate MSFT a ‘Buy’, 16 rate it a ‘Hold’. 3 analysts rates it a ‘Sell’. MSFT has a median Wall Street price target of $48.00 with a high target of $55.00.

In the past 52 weeks, shares of Redmond, Washington-based software giant have traded between a low of $38.51 and a high of $50.05 and are now at $41.15. Shares are up 6.89% year-over-year ; down 11.17% year-to-date.

Be the first to comment

Leave a Reply

Your email address will not be published.


*